The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...

“Utilizing real-world data, technology, strategic solutions, and cross-departmental partnerships will help ensure equitable access, so the right member receives the right drug at the right time and ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks. By Nina Agrawal Jennifer Le’s doctor ticked through a ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus Erythematosus (SLE). Preliminary data suggests that CAR-T therapy may ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...